Keeping the heart young
Keeping the heart young
Pioneering
better worlds
There is no cure for Heart Failure. We will change that.
> Mission, critical.
There is no cure for Heart Failure
-
7 million Americans have Heart Failure, 60 million people world-wide
-
The 5-year mortality rate upon Heart Failure diagnosis is 50%, worse than most cancers
-
Standard of Care largely addresses the symptoms of Heart Failure, not the root cause​​
We are developing novel therapeutics that address the core, molecular, underpinnings of cardiac muscle pathology to inhibit and reverse Heart Failure development and progression.
​
> Team.
Root to Canopy. Our leadership team brings talent, ideas, and experience from their time as clinicians on the front line,
scientists at top academic research institutions, and shepherds of cardiovascular pipelines in both biotech and big pharma. ​​
Leadership
Seed to Ecosystem. Supporting our therapeutic programs is a world-class Scientific Advisory Board and leading experts in RNAi, oligo chemistry, and conjugated-mediated drug delivery to the heart.
RNAi Advisors
Scientific Advisory Board
ADViRNA
Collaborator & Support
CRO in RNAi therapeutics
Deerfield Management/
CURE./NYCEDC
Support
2025 XSeed Award
Partners, Collaborators, and Support
Jonathan Kirk, Ph.D.
Strategic Partner
Loyola University of Chicago
> Pipeline.
Right Target, Right Disease, Right Modification, Right Modality. Our pipeline currently consists of two RNA-based therapeutic strategies, supported by strong foundational IP, that target two unique molecular mechanisms where there is deep scientific and clinical rationale to improve patient outcomes.
> News.
> Contact.
© 2022 GenKardia Inc.